Stay updated with breaking news from Adjuvantt dm1. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adjuvant ado-trastuzumab emtansine continued to improve overall survival and invasive disease-free survival vs trastuzumab after 8.4 years of follow-up in patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant therapy enrolled in the phase 3 KATHERINE trial. ....